These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
685 related articles for article (PubMed ID: 11526368)
1. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Steinberg JS; Martins J; Sadanandan S; Goldner B; Menchavez E; Domanski M; Russo A; Tullo N; Hallstrom A; Am Heart J; 2001 Sep; 142(3):520-9. PubMed ID: 11526368 [TBL] [Abstract][Full Text] [Related]
2. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454 [TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258 [TBL] [Abstract][Full Text] [Related]
4. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK; J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248 [TBL] [Abstract][Full Text] [Related]
5. Baseline factors predicting early resumption of driving after life-threatening arrhythmias in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. Hickey K; Curtis AB; Lancaster S; Larsen G; Warwick D; McAnulty J; Mitchell LB Am Heart J; 2001 Jul; 142(1):99-104. PubMed ID: 11431664 [TBL] [Abstract][Full Text] [Related]
6. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators. Domanski MJ; Sakseena S; Epstein AE; Hallstrom AP; Brodsky MA; Kim S; Lancaster S; Schron E J Am Coll Cardiol; 1999 Oct; 34(4):1090-5. PubMed ID: 10520795 [TBL] [Abstract][Full Text] [Related]
7. A comparison of the AVID and DAVID trials of implantable defibrillators. Sharma A; Epstein AE; Herre JM; Klein RC; Platia EV; Wilkoff B; Ledingham RB; Greene HL; Hallstrom AP; Am J Cardiol; 2005 Jun; 95(12):1431-5. PubMed ID: 15950565 [TBL] [Abstract][Full Text] [Related]
8. Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs. Singh S; Murawski MM J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):175-80. PubMed ID: 17875944 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study. Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH; Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672 [TBL] [Abstract][Full Text] [Related]
10. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study. Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM; Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132 [TBL] [Abstract][Full Text] [Related]
11. Low recurrence of syncope in patients with inducible sustained ventricular tachyarrhythmias treated with an implantable cardioverter-defibrillator. Garcia-Moran E; Mont L; Cuesta A; Matas M; Brugada J Eur Heart J; 2002 Jun; 23(11):901-7. PubMed ID: 12042012 [TBL] [Abstract][Full Text] [Related]
12. Potential impact of antiarrhythmic drugs versus implantable defibrillators on the management of ventricular arrhythmias: the Midlands trial of empirical amiodarone versus electrophysiologically guided intervention and cardioverter implant registry data. Pathmanathan RK; Lau EW; Cooper J; Newton L; Skehan JD; Garratt CJ; Griffith MJ Heart; 1998 Jul; 80(1):68-70. PubMed ID: 9764063 [TBL] [Abstract][Full Text] [Related]
13. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Bunch TJ; Mahapatra S; Murdock D; Molden J; Weiss JP; May HT; Bair TL; Mader KM; Crandall BG; Day JD; Osborn JS; Muhlestein JB; Lappe DL; Anderson JL Pacing Clin Electrophysiol; 2011 Dec; 34(12):1600-6. PubMed ID: 21895727 [TBL] [Abstract][Full Text] [Related]
14. High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator. Korte T; Köditz H; Niehaus M; Paul T; Tebbenjohanns J Pacing Clin Electrophysiol; 2004 Jul; 27(7):924-32. PubMed ID: 15271011 [TBL] [Abstract][Full Text] [Related]
15. [Initial clinical results with a novel implantable cardioverter-defibrillator: a prospective evaluation in 3 Swiss university hospitals]. Osswald S; Candinas R; Fuhrer J Schweiz Med Wochenschr; 1995 Dec; 125(50):2423-32. PubMed ID: 8553030 [TBL] [Abstract][Full Text] [Related]
16. Prospective clinical evaluation and follow-up of a cohort of consecutive VT/VF patients, using a staged-care protocol, including coronary arteriography, programmed electrical stimulation and cardiac surgery. Naccarella F; Rolli A; Carboni A; Finardi A; Aurier E; Favaro L; Contini S; Gherli T; Caponi D; Maranga SS; Lepera G; Bartoletti A G Ital Cardiol; 1999 Oct; 29(10):1142-56. PubMed ID: 10546124 [TBL] [Abstract][Full Text] [Related]
17. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ; J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671 [TBL] [Abstract][Full Text] [Related]
18. [Frequent ventricular tachycardias: antiarrhythmic drug treatment or catheter ablation?]. Tanner H; Hindricks G; Kottkamp H Herz; 2005 Nov; 30(7):613-8. PubMed ID: 16333587 [TBL] [Abstract][Full Text] [Related]
19. Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention. Das MK; Zipes DP J Cardiovasc Pharmacol; 2010 May; 55(5):438-49. PubMed ID: 20509177 [TBL] [Abstract][Full Text] [Related]
20. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death. Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]